| Customization: | Available |
|---|---|
| CAS No.: | Customization, 845533-86-0 |
| Formula: | Customization |
|
Still deciding? Get samples of US$ 400/kg
Order Sample
|
| Shipping Cost: | Contact the supplier about freight and estimated delivery time. |
|---|
| Payment Methods: |
|
|---|---|
| Support payments in USD |
| Secure payments: | Every payment you make on Made-in-China.com is protected by the platform. |
|---|
| Refund policy: | Claim a refund if your order doesn't ship, is missing, or arrives with product issues. |
|---|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Introduction:
Bedaquiline, also known by its trade name Sirturo, is a medication used for the treatment of multidrug-resistant tuberculosis (MDR-TB) in adults. It belongs to a class of drugs called diarylquinolines and works by inhibiting the adenosine triphosphate (ATP) synthase enzyme, which is vital for the growth and survival of Mycobacterium tuberculosis bacteria.
Function:
Bedaquiline is highly effective in combating MDR-TB, a form of tuberculosis that is resistant to first-line anti-TB drugs. It has demonstrated potent bactericidal activity against drug-resistant strains of Mycobacterium tuberculosis and has shown improved treatment outcomes compared to traditional therapy alone. Bedaquiline significantly reduces the time required to convert sputum cultures to negative and helps improve clinical symptoms in patients with MDR-TB.
Additionally, bedaquiline has been found to exhibit a unique mechanism of action that reduces the risk of cross-resistance with other anti-TB drugs. This is particularly important in the treatment of MDR-TB, where the use of multiple drugs in combination is essential. Bedaquiline's distinct mode of action makes it an important component of combination therapy regimens for MDR-TB.
Application:
The use of bedaquiline is recommended when other effective treatment options for MDR-TB are limited or unavailable. It is typically administered in combination with other drugs as part of a comprehensive treatment regimen. Bedaquiline has been shown to improve treatment outcomes, including increased cure rates and reduced mortality rates, in patients with MDR-TB.
Furthermore, bedaquiline has the potential to shorten the duration of MDR-TB treatment. It allows for more rapid culture conversion and helps to reduce the duration of treatment from the standard 24 months. This not only improves patient compliance but also reduces the burden on healthcare systems and resources.
1. Are you a manufacturer or trading company?
A: We are a manufacturer and welcome to visit our factory.
){kind=link}